These benefits have been proposed to be independent of changes in glycemic status (47) as the reduction in blood glucose with SGLT2 inhibition is modest (43, 45, 47), suggesting that the positive benefit of SGLT2 inhibitors could be possible in patients without overt T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.